The malarial aminopeptidases have emerged as promising new drug targets for the development of novel anti-malarial drugs. The M18AAP of Plasmodium falciparum malaria is a metallo-aminopeptidase that w
Background: Plasmodium falciparum has evolved resistance to the artemisinin component of the frontline antimalarial treatment Artemisinin-based Combination Therapy in South East Asia. Millions of live
This is the CSV files converted from XML file for \n1. the CHMI trials of plasmodium falciparum at https://doi.org/10.25919/5b5b7530a39f4 \n2. the CHMI trials of plasmodium vivax at https://doi.org/10
